Occupational exposure is known to cause 15% of asthma cases. The main treatment for occupational asthma is to stop exposure if possible. Although, remission of occupational asthma only occurs in only 30 % of patients after cessation of exposure. There is currently no way of predicting which patients will go into remission after cessation of exposure. In non-occupational asthma, the inflammatory biomarker T2 has allowed the entry into personalized medicine and can predict future exacerbations. The investigators hypothesize that T2 biomarkers could be predictive markers for remission in occupational asthma after exposure cessation. The investigators intend to carry out a follow-up study at the University Hospital of Strasbourg to perform the non-specific bronchial hyperresponsiveness test to assess remission in patients diagnosed with occupational asthma and to compare baseline T2 biomarkers in remission and non remission patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
38
T2 Biomarkers are estimated via induced sputum: Sputum is induced through increasing concentrations from 0.9 or 3% to 4% and 5% of hypertonic solution. Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge
University Hospital of Strasbourg
Strasbourg, France
Remission of occupational asthma
Remission of occupational asthma is defined by absence of nonspecific bronchial hyperresponsiveness. Assessment of nonspecific bronchial hyperresponsiveness is realized by metacholine challenge
Time frame: Day 1
Comparison of TH2-type inflammation levels
To compare the level of Th2-type inflammation in sputum from patients in remission versus patients with persistent asthma.
Time frame: Day 1
Remission of occupational rhinitis
Remission of occupational rhinitis is assessed by symptom score
Time frame: Day 1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.